392 related articles for article (PubMed ID: 34726771)
21. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
[TBL] [Abstract][Full Text] [Related]
22. Extending the US Food and Drug Administration's Postmarket Authorities.
Fernandez Lynch H; Sachs RE; Lee S; Herder M; Ross JS; Ramachandran R
JAMA Health Forum; 2023 Jun; 4(6):e231313. PubMed ID: 37294583
[TBL] [Abstract][Full Text] [Related]
23. Real-World Evidence in the Real World: Beyond the FDA.
Krause JH; Saver RS
Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
[TBL] [Abstract][Full Text] [Related]
24. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
Azebu LM
Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
[TBL] [Abstract][Full Text] [Related]
25. New Drug and Biologics Approvals in 2019: A Systematic Analysis of Patient Experience Data in FDA Drug Approval Packages and Product Labels.
Schultz-Knudsen K; Sabaliauskaite U; Hellsten J; Lassen AB; Morant AV
Ther Innov Regul Sci; 2021 May; 55(3):503-513. PubMed ID: 33230660
[TBL] [Abstract][Full Text] [Related]
26. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
27. Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications.
Chang LC; Vanheusen M; Fang X; Breder CD
Pharmacol Res; 2019 Jan; 139():166-172. PubMed ID: 30408574
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
29. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
[TBL] [Abstract][Full Text] [Related]
30. The US Food and drug administration: drug information resource for formulary recommendations.
Marchand HC; Ros BJ; Fine AM; Kremzner ME
J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
[TBL] [Abstract][Full Text] [Related]
31. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
32. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
34. Real-World Evidence, Public Participation, and the FDA.
Schwartz JL
Hastings Cent Rep; 2017 Nov; 47(6):7-8. PubMed ID: 29171057
[TBL] [Abstract][Full Text] [Related]
35. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
36. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J; Marquart J; Ruby J; Lammers A; Mailankody S; Kaestner V; Prasad V
BMJ; 2018 Mar; 360():k668. PubMed ID: 29514787
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
[TBL] [Abstract][Full Text] [Related]
38. Product Development Under FDA's Animal Rule: Understanding FDA's Expectations and Potential Implications for Traditional Development Programs.
Allio T
Ther Innov Regul Sci; 2016 Sep; 50(5):660-670. PubMed ID: 30231765
[TBL] [Abstract][Full Text] [Related]
39. Examining the Use of Real-World Evidence in the Regulatory Process.
Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH
Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770
[TBL] [Abstract][Full Text] [Related]
40. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021.
Daval CJR; Teng TW; Russo M; Kesselheim AS
JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
